Bill Thx for linking this presentation . Very important info . CABG is a very expensive procedure and even a straight forward revascularization probably costs around $20k ( including ER , Cath lab time ) . This makes Vascepa a VERY cost effective medicine .
Quote:
For statin-treated patients with elevated triglycerides and increased cardiovascular risk, icosapent ethyl significantly reduced first and subsequent revascularizations compared with placebo. We are aware of no other non-LDL based therapy in the statin era that has been shown to reduce CABG in a blinded, randomized trial
It is huge news and ICER needs to revisit the costs savings by reduced open heart CABG. The drug is an ICER A+ and significantly saves social overall health costs.
Every insurance provider should be forwarded this data ASAP.